HC
GILD icon

Hurley Capital’s Gilead Sciences GILD Stock Holding History

Hurley Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.4K Sell
518
-1
-0.2% -$132 0.03% 161
2026
Q1 		$72.3K Buy
519
+1
+0.2% +$140 0.04% 151
2025
Q4 		$63.6K Sell
518
-10
-2% -$1.22K 0.04% 155
2025
Q3 		$58.6K Buy
528
+10
+2% +$1.14K 0.03% 180
2025
Q2 		$57.4K Hold
518
– – 0.04% 146
2025
Q1 		$58K Buy
518
+358
+224% +$36.9K 0.04% 157
2024
Q4 		$15.5K Buy
+160
New +$14.4K 0.01% 243

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hurley Capital's GILD Position: Q2 2026 in Review

Hurley Capital reduced its Gilead Sciences (GILD) stake by 0.19% in Q2 2026, selling an estimated $132 and leaving 518 shares worth $65.4K. The position accounts for 0.03% of the portfolio, ranked #161.

Hurley Capital first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. The position peaked at $72.3K in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Hurley Capital held 518 shares of Gilead Sciences worth $65.4K as of Q2 2026.
  • Hurley Capital sold 1 Gilead Sciences share in Q2 2026, an estimated $132.
  • Gilead Sciences made up 0.03% of Hurley Capital's portfolio in Q2 2026, its #161 holding.
  • Hurley Capital first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • Hurley Capital's Gilead Sciences position peaked at $72.3K in Q1 2026.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.